News

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

November 14, 2017

Completed Successful EMA Meeting for DCCR in Prader-Willi Syndrome Continued Preparations to Begin Phase III ...

Read More

Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements

October 23, 2017

REDWOOD CITY, Calif. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical ...

Read More

Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome

October 12, 2017

REDWOOD CITY, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical ...

Read More
Soleno – Home